Gemcitabine in bone sarcoma resistant to doxorubicin-based chemotherapy

Sarcoma

Volumn 4, Issue 1-2, 2000, Pages 7-10

  Merimsky, Ofer ^a,b   Meller, Isaac ^a   Kollender, Yehuda ^a   Issakov, Josephine ^a   Flusser, Gideon ^a   Inbar, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Bone sarcoma; Gemcitabine

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG INDICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0033929698     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1357714X00000025     Document Type: Article

References (14)

1. 1 Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5.
2. 2 Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996;7:347-53.
3. 3 Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40.
4. 4 FDA. Quality of life matters!. News section. Ann Oncol 1995;6:854-60.
5. 5 Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule dependent antitumor effect of gemcitabine in vivo model system. Semin Oncol 1995;22:42-46.
6. 6 Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993;68:52-6.
7. 7 Merimsky O, Meller I, Kollender Y, Inbar M. Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer 1998;34:1296-7.
8. 8 Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000;45:177-81.
9. 9 Benjamin RS, Baker LH, O'Bryan RM, Moon TE, Gottlieb JA. Chemotherapy of metastatic osteosarcoma-studies by the M.D. Anderson Hospital and the Southwest Oncology Group. Cancer Treatment Rep 1978;62:237-8.
10. 10 Morgan E, Baum E, Bleyer WA, et al. Treatment of patients with metastatic osteogenic sarcomas: a report from the Children's Cancer Study Group. Cancer Treatment Rep 1984;68:661-4.
11. 11 Rosen G, et al. Cisplatin-adriamycin combination chemotherapy in evaluable osteogenic sarcoma. Proc Am Soc Clin Oncol 1982;1:173.
12. 12 Pratt CB, Champion JE, Senzer N, et al. Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin. Cancer 1985;56:1930-3.
13. 13 Patel SR, Jenkins J, Papadopoulos NE, et al. Preliminary results of a two-arm phase 2 trial of gemcitabine (Gem) in patients (Pts) with gastrointestinal leiomyosarcoma and other soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 1999;18:541a.
14. 14 Spith-Schwalbe E, Koschuth A, Grunewald R, Genvresse I, Possinger K. Gemcitabine in pretreated patients with advanced STS: preliminary results from a phase II trial. Proc Am Soc Clin Oncol 1998;17:A1976.